Foresight Diagnostics, a pioneer in ultra-sensitive minimal residual disease (MRD) detection technology, has shared its strategic outlook for 2025 and a recap of its 2024 accomplishments. The company has consistently achieved over 100% revenue growth annually since its inception, with 2024 marking a year of significant clinical and regulatory milestones.
2025 Goals:
- Revenue Growth: Aim to increase revenue through new and expanded partnerships with biopharma and academic institutions, focusing on the regulated use of Foresight CLARITY™, including companion diagnostic development and MRD-based endpoints in global clinical trials.
- Commercial Launch Preparation: Secure reimbursement for Foresight CLARITY™ in lymphoma and solidify the launch strategy for its commercialization.
- Advancement in Solid Tumors: Progress Foresight CLARITY™ for solid tumors through strategic partnerships and introduce real-time testing as a laboratory-developed test (LDT).
2024 Highlights:
- Revenue and Partnerships: Achieved a 100% revenue growth in 2024, with over 60 contracts signed with more than 20 pharmaceutical and 10 academic partners.
- FDA Approval: Received Investigational Device Exemption (IDE) approval from the FDA for the use of Foresight CLARITY™ in the ALPHA3 clinical trial, marking a significant regulatory milestone.
- Corporate Expansion: Moved to a new corporate headquarters and CLIA-certified lab in Boulder, CO, enhancing testing capabilities with an average turnaround time of 7 days.
- Funding: Closed a $33 million Series B funding round, bringing the total venture funding to $86 million, to accelerate the development of Foresight CLARITY™ in solid tumors.
- Clinical Evidence: Demonstrated the clinical performance of Foresight CLARITY™ in early-stage lung and breast cancers, showcasing its potential to improve patient outcomes through MRD detection.
Foresight Diagnostics is set to present at the 43rd Annual J.P. Morgan Healthcare Conference and will be available for meetings during the LifeSci Corporate Access Event in January 2025. The company continues to focus on delivering innovative diagnostics for cancer patients, aiming to empower therapeutic decisions that enhance patient outcomes.
